Posted by admin on Aug 19th, 2022

Shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY – Get Rating) have been assigned a consensus rating of “Hold” from the twelve ratings firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $48.11.

A number of analysts recently weighed in on XRAY shares. StockNews.com lowered shares of DENTSPLY SIRONA from a “buy” rating to a “hold” rating in a research note on Monday. HC Wainwright cut their target price on shares of DENTSPLY SIRONA from $58.00 to $48.00 and set a “hold” rating on the stock in a research note on Friday, April 22nd. The Goldman Sachs Group cut their target price on shares of DENTSPLY SIRONA from $42.00 to $41.00 and set a “neutral” rating on the stock in a research note on Thursday, July 21st. William Blair lowered shares of DENTSPLY SIRONA from a “market perform” rating to an “underperform” rating in a research note on Friday, August 5th. Finally, UBS Group upgraded shares of DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and cut their target price for the stock from $58.00 to $47.00 in a research note on Wednesday, June 1st.

A number of hedge funds have recently modified their holdings of the business. SOA Wealth Advisors LLC. lifted its holdings in shares of DENTSPLY SIRONA by 26,666.7% during the first quarter. SOA Wealth Advisors LLC. now owns 803 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 800 shares during the period. Parkside Financial Bank & Trust lifted its holdings in shares of DENTSPLY SIRONA by 163.7% during the first quarter. Parkside Financial Bank & Trust now owns 915 shares of the medical instruments supplier’s stock worth $46,000 after purchasing an additional 568 shares during the period. Van ECK Associates Corp acquired a new stake in shares of DENTSPLY SIRONA during the second quarter worth $41,000. Dixon Hughes Goodman Wealth Advisors LLC acquired a new stake in DENTSPLY SIRONA in the first quarter valued at $79,000. Finally, Covestor Ltd acquired a new stake in DENTSPLY SIRONA in the fourth quarter valued at $90,000. 94.79% of the stock is currently owned by hedge funds and other institutional investors.

Shares of XRAY opened at $36.36 on Friday. The stock has a market capitalization of $7.83 billion, a PE ratio of 21.51, a P/E/G ratio of 2.98 and a beta of 0.91. DENTSPLY SIRONA has a 1 year low of $33.78 and a 1 year high of $63.10. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.03 and a current ratio of 1.45. The company’s 50-day simple moving average is $35.98 and its 200-day simple moving average is $42.94.

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 14th. Stockholders of record on Friday, September 30th will be given a dividend of $0.125 per share. The ex-dividend date of this dividend is Thursday, September 29th. This represents a $0.50 dividend on an annualized basis and a dividend yield of 1.38%. DENTSPLY SIRONA’s dividend payout ratio (DPR) is presently 29.59%.

DENTSPLY SIRONA Inc designs, develops, manufactures, distributes, and sells various dental products and technologies for professional dental market worldwide. It offers dental equipment, including treatment centers, imaging equipment, motorized dental handpieces, and other instruments; imaging equipment; treatment centers comprising basic dentist chairs, sophisticated chair-based units with integrated diagnostic, hygiene and ergonomic functionalities, and specialist centers; and lab equipment, such as amalgamators, mixing machines, and porcelain furnaces.

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.

F45 Training Holdings Inc. (NYSE:FXLV) Receives Average Recommendation of “Hold” from Analysts

Precision BioSciences, Inc. (NASDAQ:DTIL) Given Consensus Recommendation of “Moderate Buy” by Brokerages